CTSO - CIK 0001175151
Cytosorbents Corp (CTSO) reported revenue of $37.06M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $37.06M | +4.1% |
| FY 2024 | $35.59M | +14.5% |
| FY 2023 | $31.08M | -10.4% |
| FY 2022 | $34.69M | -19.6% |
| FY 2021 | $43.17M | +5.3% |
| FY 2020 | $41.00M | +64.4% |
| FY 2019 | $24.95M | +10.9% |
| FY 2018 | $22.50M | +48.5% |
| FY 2017 |
Cytosorbents Corp (CTSO) reported revenue of $37.06M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Cytosorbents Corp's revenue grew from $36.08K to $37.06M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.15M |
| +59.0% |
| FY 2016 | $9.53M | +98.8% |
| FY 2015 | $4.79M | +16.2% |
| FY 2014 | $4.12M | +70.2% |
| FY 2013 | $2.42M | +80.4% |
| FY 2012 | $1.34M | +3622.3% |
| FY 2011 | $36.08K | - |